Wedbush started coverage on shares of TScan Therapeutics (NASDAQ:TCRX – Get Rating) in a research report sent to investors on Wednesday morning, The Fly reports. The brokerage issued an outperform rating and a $8.00 price target on the stock. Separately, HC Wainwright restated a buy rating and set a $15.00 price objective on shares of […]
TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Rating) major shareholder Lynx1 Capital Management Lp sold 25,400 shares of the stock in a transaction that occurred on Wednesday, May 31st. The stock was sold at an average price of $2.52, for a total value of $64,008.00. Following the completion of the sale, the insider now directly owns […]
TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Rating) major shareholder Lynx1 Capital Management Lp sold 25,400 shares of TScan Therapeutics stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $2.52, for a total value of $64,008.00. Following the transaction, the insider now directly owns 5,224,600 shares of the […]
TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Rating) – Stock analysts at HC Wainwright cut their Q2 2023 earnings estimates for TScan Therapeutics in a research note issued to investors on Thursday, May 11th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($1.04) per share for the quarter, down from […]
TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Rating) was the target of a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 91,700 shares, a drop of 24.7% from the March 31st total of 121,700 shares. Based on an average daily trading volume, of 148,900 shares, […]